Please login to the form below

Not currently logged in
Email:
Password:

anaemia

This page shows the latest anaemia news and features for those working in and with pharma, biotech and healthcare.

First-line ovarian approval cements AZ’s Lynparza lead

First-line ovarian approval cements AZ’s Lynparza lead

And in another positive development, AZ also announced today that two additional phase 3 trials of its just-approved drug for anaemia in chronic kidney disease patients – roxadustat – backed the efficacy

Latest news

More from news
Approximately 7 fully matching, plus 137 partially matching documents found.

Latest Intelligence

  • China: AstraZeneca’s new engine for growth and innovation China: AstraZeneca’s new engine for growth and innovation

    FibroGen in China for patients with anaemia in chronic kidney disease.

  • Leo has its eyes on the prize Leo has its eyes on the prize

    major depressive disorder and iron-deficiency anaemia.

  • Deal Watch - May 2017 Deal Watch - May 2017

    It is not known why in December 2015 the territorial rights granted to Mitsubishi for vadadustat for treatment of anaemia, were limited to Japan, SE Asia and India.  From a ... 1, 050. Akebia (US). Otsuka (JP). Licence expansion selected countries.

  • Deal Watch December 2016 Deal Watch December 2016

    1, 000. Akebia (US). Otsuka (Japan). Licence (US). Vadadustat: oral hypoxia-inducible factor (HIF) stabiliser in phase III for anaemia of chronic kidney disease.

  • Focusing on value Focusing on value

    in Brazil, involving the iron deficiency related anaemia treatment Anemidox/Confer and liver protector Hepabionta.

More from intelligence
Approximately 0 fully matching, plus 13 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Joined-up thinking on anaemia

    Iron deficiency anaemia is very common in inflammatory bowel disease (IBD) and can seriously reduce people’s quality of life, but it’s often under-treated. ... Pharmacosmos is committed to improving the lives of patients with iron deficiency anaemia.

  • Living with Crohn's disease: a patient perspective

    It’s also a very individual condition. The most common symptoms are not only diarrhoea, but also tiredness and fatigue, abdominal pain, mouth ulcers, anaemia, loss of appetite, and weight loss.

  • Patient Power: Too Much of a Good Thing?

    It commonly causes abdominal pain, diarrhoea, weight loss and vomiting but because it affects the immune system it can cause other problems such as anaemia, arthritis, lack of concentration, tiredness and

  • Dovetail

    Joined-up thinking on anaemia. ... Iron deficiency anaemia is very common in inflammatory bowel disease (IBD) and can seriously reduce people’s quality of life, but it’s often under-treated.

More from PMHub
Approximately 1 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
wethepeople

wethepeople are bringing human appeal back to brand communications. Our approach allows us to create strategies, ideas and experiences that...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics